LAMEA Actinic Keratosis Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class, By Therapy (Surgery, Topical and Photodynamic Therapy), By End-use (Hospitals, Private Clinics, Homecare and Others), By Country and Growth Forecast, 2022 - 2028

The Latin America, Middle East and Africa Actinic Keratosis Treatment Market should witness market growth of 6.5% CAGR during the forecast period (2022-2028).

Due to factors including the higher occurrence of actinic keratosis and the widespread availability of generic medications for the treatment of the condition, the market is expected to have growth prospects. Additionally, growing public awareness of actinic keratosis and several strategic moves made by market participants are driving the market.

The extensive use of actinic keratosis drugs has been prompted by a greater understanding of the diagnostic methods and therapeutic approaches for this condition. Over the coming years, the market penetration of field-directed medications such as 5-fluorouracil, Ingenol mebutate, diclofenac, and Imiquimod is expected to increase.

The results of photodynamic therapy were found to be more favorable than those of cryotherapy in regard to appearance. Actinic keratosis treatments' widespread accessibility and availability are anticipated to significantly boost this growth of the market.

Acral lentiginous melanoma (ALM) is a significant melanoma subtype, in which cells become cancerous, in Latin America. According to several case studies and case-control studies, trauma is a potential risk for melanomas that develop at acral sites, and more particularly for ALM. A higher incidence of foot and hand skin cancers and/or ALM has also been linked to harmless nevi on the toes or soles. The majority of Colombians have different traits with a substantially greater percentage of acral melanomas, extremely final stages at diagnosis, and subpar prognosis.

The Brazil market dominated the LAMEA Actinic Keratosis Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $132.4 Million by 2028. The Argentina market is experiencing a CAGR of 7% during (2022-2028). Additionally, The UAE market would exhibit a CAGR of 6.2% during (2022-2028).

Based on Drug Class, the market is segmented into Nucleoside Metabolic Inhibitor, NSAIDs, Immune Response Modifiers, Photoenhancers and Others. Based on Therapy, the market is segmented into Surgery, Topical and Photodynamic Therapy. Based on End-use, the market is segmented into Hospitals, Private Clinics, Homecare and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Almirall, S.A, LEO Pharma A/S, Biofrontera AG, Sun Pharmaceuticals Industries Ltd., 3M Company, Bausch Health Companies, Inc., Novartis AG, Viatris, Inc., and Galderma S.A.

Scope of the Study

By Drug Class

• Nucleoside Metabolic Inhibitor
• NSAIDs
• Immune Response Modifiers
• Photoenhancers
• Others

By Therapy

• Surgery
• Topical
• Photodynamic Therapy

By End-use

• Hospitals
• Private Clinics
• Homecare
• Others

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Almirall, S.A
• LEO Pharma A/S
• Biofrontera AG
• Sun Pharmaceuticals Industries Ltd.
• 3M Company
• Bausch Health Companies, Inc.
• Novartis AG
• Viatris, Inc.
• Galderma S.A.

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free